

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|-----------------------------|---------------|-------------------------|---------------------|------------------|
| . 10/615,945 | 07/10/2003 | Nitzan Zafrir-Pachter | 25906 | 1097 |
| 75 | 90 08/23/2006 | | EXAMINER | |
| Martin D. Moynihan | | | HO, UYEN T | |
| PRTSI, Inc. P. O. Box 16446 | | | ART UNIT | PAPER NUMBER |
| Arlington, VA 22215 | | | 3731 | <u> </u> |
| | | DATE MAILED: 08/23/2006 | | |

Please find below and/or attached an Office communication concerning this application or proceeding.

| | Application No. | Applicant(s) | | | | |
|---|--|-------------------------------------|--|--|--|--|
| | 10/615,945 | ZAFRIR-PACHTER ET AL. | | | | |
| Office Action Summary | Examiner | Art Unit | | | | |
| • | (Jackie) Tan-Uyen T. Ho | 3731 | | | | |
| The MAILING DATE of this communication app | | | | | | |
| Period for Reply | | | | | | |
| A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). | | | | | | |
| Status | | | | | | |
| 1) Responsive to communication(s) filed on 10 Ju | <u>ıly 2003</u> . | | | | | |
| 2a) ☐ This action is FINAL . 2b) ☑ This | action is non-final. | | | | | |
| 3) Since this application is in condition for allowar | 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is | | | | | |
| closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. | | | | | | |
| Disposition of Claims | | | | | | |
| 4) Claim(s) 1-20 is/are pending in the application. | | | | | | |
| 4a) Of the above claim(s) is/are withdrawn from consideration. | | | | | | |
| 5) Claim(s) is/are allowed. | 5) Claim(s) is/are allowed. | | | | | |
| 6) Claim(s) <u>1-20</u> is/are rejected. | | | | | | |
| 7) Claim(s) is/are objected to. | | | | | | |
| 8) Claim(s) are subject to restriction and/o | r election requirement. | | | | | |
| Application Papers | | | | | | |
| 9) The specification is objected to by the Examiner. | | | | | | |
| 10) The drawing(s) filed on is/are: a) acce | 10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner. | | | | | |
| Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). | | | | | | |
| Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). | | | | | | |
| 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. | | | | | | |
| Priority under 35 U.S.C. § 119 | | | | | | |
| 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). | | | | | | |
| a) All b) Some * c) None of: | | | | | | |
| 1. Certified copies of the priority documents have been received. | | | | | | |
| 2. Certified copies of the priority documents have been received in Application No | | | | | | |
| 3. Copies of the certified copies of the priority documents have been received in this National Stage | | | | | | |
| application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. | | | | | | |
| , , , , , , , , , , , , , , , , , , , | | | | | | |
| | | | | | | |
| | | | | | | |
| Attachment(s) | n □ 1-4- 1- 0 | · (DTO 442) | | | | |
| 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) | 4) Interview Summary Paper No(s)/Mail D | | | | | |
| 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) | 5) 🔲 Notice of Informal F | Patent Application (PTO-152) | | | | |
| Paper No(s)/Mail Date <u>9/30/03</u> . U.S. Patent and Trademark Office | 6) | | | | | |
| | etion Summary Pa | art of Paper No./Mail Date 20060811 | | | | |

Art Unit: 3731

DETAILED ACTION

Information Disclosure Statement

1. The information disclosure statement (IDS) submitted on 9/30/03 is acknowledged and considered.

Double Patenting

2. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

3. Claims 1-20 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 5-24 of U.S. Patent No. 6,673,089. Although the conflicting claims are not identical, they are not patentably distinct from each other because the claims of this application are anticipated by the claimed invention of the patent.

Application/Control Number: 10/615,945 Page 3

Art Unit: 3731

Claim Rejections - 35 USC § 103

4. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all

obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains.

Patentability shall not be negatived by the manner in which the invention was made.

5. Claims 1-20 are rejected under 35 U.S.C. 103(a) as being unpatentable over

Dubrul (6,258,115). Dubrul disclose a stent-graft or filter comprising a tubular

configuration as claimed having plurality of openings there through. Although, Dubrul

does not clear disclose a stent-graft or filter including a filter membrane/deflector or graft

attached to the stent. It is well known in the art that a stent-graft or a emboli filter

comprising a stent structure as a base element having anchor portions and support

portions for supporting and anchoring the graft or filter membrane at a treated site and

wherein the graft or filter element attached to stent structure, struts or filaments by

stitches as well as the filter or graft having the pores size in the range as claimed in

order to trap the emboli materials in blood streams. Therefore, it would have been

obvious to one having ordinary skill in the art at the time the invention was made to

construct the stent-graft or filter of Dubrul from the well-known materials and method in

order to provide stent-graft or filter with all requirements to perform the function of a

stent-graft or filter. Doing so would result the claimed inventions.

6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to (Jackie) Tan-Uyen T. Ho whose telephone number is 571-272-4696. The examiner can normally be reached on MULTIFLEX Mon. to Sat..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, ANHTUAN NGUYEN can be reached on 571-272-4963. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

(Jackie) Tan-Uyen T. Ho

Primary Examiner

Art Unit 3731